The study shows the antihistaminic and anti-inflammatory efficient treatment with olopatadina 0.1%.The study group consisting of 30 patients evaluated in the ophthalmological ambulatory between the period of april-august 2007 were diagnosed with acute seasonal allergic conjunctivites. Ig E and seric eosinofiles were quantified for all patients and the severity of conjunctivitis was evaluated by summing up the scores of the cardinal signs of allergic conjunctivitis: itching, conjunctival hyperemia and tearing. For a month every patients was treated with olopatadina 0.1% 2x1 drop/day. They were evaluated in day 1, day 8 and day 30. The tolerance of the treatment was judged by the reduced symptoms after olopatadine instilation.The score in day 1 was higher in children under 16 years of age who presented itching and tearing. After day 8 of treatment the scores droped significantly and after a month the scores decreased highly to a percentage from 60-85%.Choosing the best therapy in allergic conjunctivitis involves studying the mechanism implicated in triggering the allergy Olopatadina 0.1% with its double mechanism has proven to be efficient in moderate seasonal allergic conjunctivitis.